Skip to main content

Hidradenitis Suppurativa Content

Derm Q&A
Jessica Garlewicz, Associate Digital Editor
Steven R. Cohen, MD, MPH, met with The Dermatologist to discuss the efficacy of high dose intralesional triamcinolone (ILTAC) for hidradenitis suppurativa.
A study published in the Journal of Allergy and Clinical Immunology found that hidradenitis suppurativa tunnels are a source of inflammation, often causing significant burden in patients with the disease.
An international group of 31 experts in hidradenitis suppurativa reached consensus agreements on the definitions for morphological features of HS lesions, clarifying terms frequently evaluated in HS clinical trials.
According to a study published in Dermatology, the clinical staging systems for hidradenitis suppurativa (HS) have poor interrater reliability and possibly underestimate disease activity.
While research works toward understanding the disease pathophysiology, a more immediate need to understand the intersection of HS and COVID-19 has taken precedent.
A study published in JAMA Dermatology sought to describe the demographics, clinical features, treatment, associated comorbidities, and outcomes within a large cohort of pediatric patients with HS.
A study published in the International Journal of Dermatology has reported that patients treated with a high dose of intralesional triamcinolone (ILTAC) for hidradenitis suppurativa (HS) have expressed improvements in disease state, quality of life, and overall satisfaction.
According to a recent study, inflammatory phenotype is associated with high C-reactive protein levels, showcasing the increased cardiovascular risk in patients with hidradenitis suppurativa.
Do you routinely screen for these diseases in your patients with HS? Let us know in the poll below!
Power-Doppler ultrasound assesses the persistence of fistulous tracts under treatment with adalimumab in hidradenitis suppurativa.
Back to Top